BarryTicho_e.009

Lab Rats to Unicorns

Episode 009 is ambitious; by interviewing Barry Ticho, John has the opportunity to discuss and share a more comprehensive description of the relationship between entrepreneurial, R&D and clinical experience at both large pharma and emerging biotech companies.

Barry is the Chief Medical Officer at Stoke Therapeutics––a company addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines––as well as a founder and board member at Verve Therapeutics which aims to protect the world from heart disease.

Prior to his current positions, he was the head of development of mRNA treatments for cardiovascular and metabolic diseases at Moderna Therapeutics as well as head of external R&D innovation for cardiovascular and metabolic diseases at Pfizer (two widely talked about companies right now). He was also vice president of clinical development at Biogen.

Barry spent time at the University of Chicago where he received his MD and PhD. He then completed his pediatrics training at Northwestern University and a cardiology fellowship at Children’s hospital in Boston. He stuck to the east coast following his move to Boston where he worked on the clinical staff at Harvard Medical School and Massachusetts General Hospital and conducted laboratory research.

His experience centers around therapeutics across a range of modalities especially in the area of mRNA. Hearing about his continuum of experiences will help the LRTU audience connect some dots.